Cassava Sciences Halts Alzheimer's Drug Trials Amid Stock Plunge
TL;DR Summary
A clinical trial for a controversial Alzheimer's drug has been halted due to disappointing results, raising concerns about its efficacy and future in the pharmaceutical market.
- Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results The New York Times
- Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails Barron's
- Cassava Sciences and its Alzheimer’s drug are done. The damage lingers STAT
- Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops Investor's Business Daily
- Cassava shares sink on plans to stop Alzheimer's drug studies Reuters.com
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
10%
29 → 26 words
Want the full story? Read the original article
Read on The New York Times